Citations

Clear

390 citation(s) found for "Loftus, E".

S906 Efficacy and Durability of Ozanimod by Baseline Endoscopic Disease Activity in Advanced Therapy–Naive Ulcerative Colitis Patients Suboptimally Controlled on Conventional Therapies
D’Haens, Geert , Blumenstein, Irina , Wolf, Douglas C. , Abraham, Bincy , Jain, Anjali , Wu, Hsiuanlin, Osterman, Mark T. , Long, Millie D. , Rubin, David T. , Siegmund, Britta , Irving, Peter Miles , Siegel, Corey A , Loftus, Edward V. , Caldera, Freddy , Peyrin‐Biroulet, Laurent

Mayo Clinic

American Journal of Gastroenterology | October 18, 2023 | Volume: 118 | Issue: 10S | Pages: S675-S676

10.14309/01.ajg.0000953264.39304.09 Get It

S845 Risankizumab Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Efficacy and Safety in the Randomized Phase 3 INSPIRE Study
Louis, Édouard , Parkes, Gareth , Ferrante, Marc , Takeuchi, Ken , Levine, Phillip, Kalabic, Jasmina , Neimark, Ezequiel, Wallace, Kori, Duan, W. Rachel, Biedermann, Luc , Melmed, Gil , Melmed, Gil Y , Louis, Edouard , Panaccione, Remo , Peyrin‐Biroulet, Laurent , Siegmund, Britta , Chen, Su , Armuzzi, Alessandro , Loftus, Edward V. , Schreiber, Stefan

Mayo Clinic

American Journal of Gastroenterology | October 18, 2023 | Volume: 118 | Issue: 10S | Pages: S624-S625

10.14309/01.ajg.0000953020.05891.05 Get It

S244 Open Label Experience With Bismuth Subsalicylate in Patients With Microscopic Colitis
Pardi, Ryan, Tremaine, William J., Khanna, Sahil , Pardi, Darrell S. , Tariq, Raseen , Loftus, Edward V. , Saha, Srishti

Mayo Clinic

American Journal of Gastroenterology | October 18, 2023 | Volume: 118 | Issue: 10S | Pages: S183-S183

10.14309/01.ajg.0000950616.02611.e6 Get It

Home-based Biologic Infusions for Inflammatory Bowel Disease: Are We Ready for Prime Time?
Tariq, Raseen , Loftus, Edward V.

Mayo Clinic

Inflammatory Bowel Diseases | October 11, 2023 | Volume: 30 | Issue: 9 | Pages: 1633-1634

10.1093/ibd/izad240 | PMID 37819733 Get It

Effectiveness and Safety of Antiobesity Medications in Patients With Obesity and Inflammatory Bowel Disease
Pham, J. , Ghusn, Wissam , Acosta, Andrés , Loftus, Edward V. , Johnson, Amanda M. , Pham, Jonathan T , Ghusn, Wissam , Loftus, Edward V , Acosta, Andres

Mayo Clinic

American Journal of Gastroenterology | October 9, 2023 | Volume: 119 | Issue: 6 | Pages: 1197-1200

10.14309/ajg.0000000000002490 | PMID 37811776 Get It

INTRODUCTION: Limited data exist evaluating antiobesity medications (AOM) in patients with inflammatory bowel disease (IBD). METHODS: We performed a case-control study evaluating the effectiveness and safety of AOM in patients with IBD with obesity, matched to non-IBD controls. RESULTS: After 12 months, the case (n = 36) and control (n = 36) groups achieved similar percent total body weight loss of −6.9 ± 8.3 and −8.1 ± 7.0 ( P = 0.30), respectively. Side effect profiles were similar between groups. Seven patients experienced an IBD flare, all managed medically. DISCUSSION: AOM use in patients with IBD demonstrated similar effectiveness and safety when compared with that observed in the non-IBD population.
Fecal Microbiota Transplantation Is Effective for Postcolectomy Recurrent Clostridioides difficile Infection
Cho, Janice , Roque, Maria Vazquez , Orenstein, Robert , Loftus, Edward V. , DiBaise, John K. , Pardi, Darrell S. , Khanna, Sahil , Loftus, Edward V

Mayo Clinic

Journal of Gastrointestinal Infections | September 22, 2023 | Volume: 12 | Issue: 01 | Pages: 036-040

10.1055/s-0042-1757197 Get It

Background The outcomes from fecal microbiota transplantation (FMT) for recurrent Clostridioides difficile infection (rCDI) in patients after complete or partial colectomy are not well-defined. Objectives We sought to report our experience with FMT for rCDI in patients who have undergone colectomy. Methods Descriptive analyses of FMT outcomes from 2014 to 2020 were performed in patients who previously had undergone complete or partial colectomy. Results Twenty-nine patients with prior colectomy for inflammatory bowel disease, malignancy, slow-transit constipation refractory to medical therapy, or fulminant CDI underwent FMT for rCDI. Two patients (6.9%) had rCDI within 8 weeks post-FMT. Seven had CDI beyond 8 weeks (median 10 months) with 71% related to antibiotic exposure post-FMT, suggesting a 69% overall success. Conclusion FMT resolves rCDI in most patients after colectomy with subsequent antibiotic exposure predicting CDI after FMT.
Integrated safety analysis of filgotinib for ulcerative colitis: Results from SELECTION and SELECTIONLTE
Schreiber, Stefan , Rogler, Gerhard , Watanabe, Mamoru , Vermeire, Séverine , Maaser, Christian , Faes, Margaux , Hoek, Paul Van , Hsieh, Jeremy, Moerch, Ulrik, Haas, Angela de, Rudolph, Christine , Oortwijn, Alessandra , Loftus, Edward V. , Danese, Silvio , Oortwijn, Alessandra , Loftus, Edward V , Vermeire, Séverine , Danese, Silvio , Zhou, Yan

Mayo Clinic

Alimentary Pharmacology & Therapeutics | September 18, 2023 | Volume: 58 | Issue: 9 | Pages: 874-887

10.1111/apt.17674 | PMID 37718932 Get It

Summary Background Filgotinib 200 mg (FIL200) is an approved treatment for adults with moderately to severely active ulcerative colitis (UC). Aim To report integrated safety data from the phase 2b/3 SELECTION study (NCT02914522) and its ongoing long‐term extension study SELECTIONLTE (NCT02914535). Methods Safety outcomes were analysed in adults with moderately to severely active UC who received FIL200, filgotinib 100 mg (FIL100) or placebo once daily throughout the 11‐week SELECTION induction study, the 47‐week SELECTION maintenance study (if applicable) and SELECTIONLTE (if applicable). Exposure‐adjusted incidence rates (EAIRs) per 100 censored patient‐years of exposure with 95% confidence intervals were reported for treatment‐emergent adverse events (AEs). Certain AE data were presented in subgroups, including age and prior biologic exposure status. Results This interim analysis included 1348 patients representing 3326.2 patient‐years of exposure. Baseline characteristics of patients entering SELECTION were similar across treatment groups. EAIRs for serious infection, thromboembolic events and major adverse cardiovascular events (MACE) were consistently low across treatment groups. Most patients with MACE had cardiovascular risk factors. The EAIR for herpes zoster was numerically higher for FIL200 than for placebo. Infection incidences were numerically higher in biologic‐experienced than biologic‐naive patients. Higher incidences of certain AEs in patients 65 years of age or older were as expected. Four deaths occurred, including three cardiovascular deaths, none of which was considered related to filgotinib. Conclusion FIL200 and FIL100 were well tolerated with no unexpected safety signals in patients with moderately to severely active UC, regardless of previous biologic exposure or age. ClinicalTrials.gov Identifiers (NCT numbers) NCT02914522, NCT02914535.
Practical Primer Addressing Real-World Use Scenarios of Subcutaneous Vedolizumab in Ulcerative Colitis and Crohn’s Disease: Post Hoc Analyses of VISIBLE Studies
Sandborn, William J. , Chen, Jingjing , Kisfalvi, Krisztina, Loftus, Edward V. , D’Haens, Geert , Candela, Ninfa , Lasch, Karen, Wolf, Douglas C. , Uddin, Sharif , Danese, Silvio , Loftus, Edward V , Danese, Silvio

Mayo Clinic

Crohn's & Colitis 360 | August 15, 2023 | Volume: 5 | Issue: 3 | Pages: No page available

10.1093/crocol/otad034 | PMID 37636008 Get It

Abstract Background Vedolizumab, an anti-α4β7 integrin approved for intravenous (IV) treatment of moderately to severely active ulcerative colitis (UC) and Crohn’s disease (CD), was evaluated as a subcutaneous (SC) formulation in maintenance therapy for UC and CD in phase 3 VISIBLE 1, 2, and open-label extension studies, and recently approved in Europe, Australia, and Canada. Our aim was to evaluate efficacy and safety of IV and SC vedolizumab in clinically relevant UC and CD scenarios. Methods Post hoc data analyses from VISIBLE trials examined: (1) whether baseline characteristics predict clinical response to 2 vs 3 IV vedolizumab induction doses; (2) efficacy and safety of switching during maintenance vedolizumab IV to SC in patients with UC; (3) vedolizumab SC after treatment interruption of 1–46 weeks; (4) increasing dose frequency of vedolizumab SC from every 2 weeks (Q2W) to every week (QW) after disease worsening. Results No baseline characteristics were identified as strong predictors of response to 2 vs 3 vedolizumab infusions. Most patients achieved clinical response after 2 or 3 doses of IV vedolizumab maintained with SC treatment. Clinical remission and response rates were maintained in patients transitioned from maintenance vedolizumab IV to SC treatment. Of patients with UC, ≥75% achieved response following resumption after dose interruption. Escalation to QW dosing resulted in ≥45% of patients regaining response after loss while receiving vedolizumab Q2W. Conclusions Clinical real-world scenarios with vedolizumab SC were reviewed using VISIBLE studies data. Vedolizumab SC provides an additional dosing option for patients with UC and CD.
Characteristics, Clinical Outcomes, and Prognosis of Anal and Pouch-related Carcinoma in Patients With Crohn’s Disease
Suttichaimongkol, Tanita , Loftus, Edward V.

Mayo Clinic

Inflammatory Bowel Diseases | June 8, 2023 | Volume: 30 | Issue: 4 | Pages: 547-553

10.1093/ibd/izad104 | PMID 37279944 Get It

Abstract Background This study described the clinical characteristics, outcomes, and prognosis of Crohn’s disease (CD) patients with anal cancer in a tertiary referral center. Methods The electronic medical records of 35 adult CD patients, including CD of the pouch, with anal carcinoma evaluated at Mayo Clinic Rochester, Florida, or Arizona between January 1989 and August 2022 were retrospectively reviewed. Results Before cancer diagnosis, patients with pouch-related carcinoma had a shorter median duration of inflammatory bowel disease than those with anal carcinoma (10 vs 26 years). Twenty-six patients (74%) had perianal diseases or rectovaginal fistula, and 35% had a history of human papillomavirus infection. Twenty-one patients (60%) were diagnosed with cancer by anal examination under anesthesia (EUA). More than half of adenocarcinomas were mucinous. Sixteen patients (47%) were American Joint Committee on Cancer (AJCC) Tumor Nodes Metastasis (TNM) stage 3, and 83% were treated by surgery. At last follow-up, 57% of patients were alive without cancer. The 1-, 3- and 5-year overall survival rates were 93.8% (95% confidence interval [CI], 85.7%-100%), 71.5% (95% CI, 56.4%-90.7%), and 67.7% (95% CI, 51.2%-87.7%), respectively. Advanced AJCC TNM stage (hazard ratio, 3.20 per stage; 95% CI, 1.05-9.72; P = .040) was significantly associated with increased risk of death, whereas the period of cancer diagnosis in 2011-2022 (HR, relative to 1989-2000, 0.16; 95% CI, 0.04-0.72; P = .017) was significantly related to decreased risk of death. Conclusions Anal and pouch-related carcinomas were rare complications of CD, and long-standing perianal diseases were an important risk factor. Anal EUA improved the diagnostic yield. Newer cancer treatment strategies and surgery were associated with excellent survival outcome.